On Oct 25, major Wall Street analysts update their ratings for $Arcus Biosciences (RCUS.US)$, with price targets ranging from $20 to $46.
Morgan Stanley analyst Terence Flynn maintains with a buy rating, and maintains the target price at $35.
BofA Securities analyst Jason Zemansky maintains with a hold rating, and maintains the target price at $22.
Citi analyst Yigal Nochomovitz maintains with a buy rating, and adjusts the target price from $38 to $46.
Barclays analyst Peter Lawson maintains with a buy rating, and adjusts the target price from $25 to $29.
Truist Financial analyst Asthika Goonewardene maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $Arcus Biosciences (RCUS.US)$'s main analysts recently are as follows:
The recent data on HIF2alpha confirmed that the overall response rate is comparable with that of competitors. There are several avenues to potentially improve this rate, considering that there are still five patients participating in the study.
The presentation of the first clinical activity data for casdatifan at the 2024 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics has provided an evolving yet very favorable view of the clinical benefit/risk ratio. The inclusion of casdatifan in the model for post-immunotherapy treatment in metastatic clear cell renal cell carcinoma, with a projected success rate and anticipated launch year, reflects the analyst's positive outlook on its potential.
Here are the latest investment ratings and price targets for $Arcus Biosciences (RCUS.US)$ from 6 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美东时间10月25日，多家华尔街大行更新了$Arcus Biosciences (RCUS.US)$的评级，目标价介于20美元至46美元。
摩根士丹利分析师Terence Flynn维持买入评级，维持目标价35美元。
美银证券分析师Jason Zemansky维持持有评级，维持目标价22美元。
花旗分析师Yigal Nochomovitz维持买入评级，并将目标价从38美元上调至46美元。
巴克莱银行分析师Peter Lawson维持买入评级，并将目标价从25美元上调至29美元。
储亿银行分析师Asthika Goonewardene维持买入评级。
此外，综合报道，$Arcus Biosciences (RCUS.US)$近期主要分析师观点如下：
关于HIF2alpha的最新数据证实，总体反应率与竞争对手相当。有几种潜在途径可以提高这一比率，考虑到仍有五名患者参与研究。
在2024年EORTC-新华保险-国家癌症研究中心分子靶点与癌症治疗研讨会上，首次展示了casdatifan的临床活动数据，为临床效益/风险比提供了逐渐变好但非常有利的观点。将casdatifan纳入转移性透明细胞肾细胞癌免疫治疗后治疗模型中，具有预测的成功率和预期的推出年份，反映了分析师对其潜力的积极展望。
以下为今日6位分析师对$Arcus Biosciences (RCUS.US)$的最新投资评级及目标价：
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
